本文由小咖机器人翻译整理

期刊来源：Lancet

原文链接：https://doi.org/10.1016/S0140-6736(23)02705-8

摘要内容如下：

在高收入国家，B细胞淋巴瘤的发病率为每年每10万人中有20个新病例。它们可以影响任何器官，并以不同的临床表现和病程为特征，从无症状到惰性，再到非常具有侵袭性的病例。自2017年《柳叶刀》杂志上一次对B细胞非霍奇金淋巴瘤这一主题进行回顾以来，对这一异质性恶性肿瘤的生物学背景的深入了解、新诊断方法的可用性以及新的靶向和免疫治疗方法的开发和实施提高了我们治疗患者的能力。本次研讨会概述了B细胞非霍奇金淋巴瘤的病理学、分类和预后，并总结了关于成熟B细胞非霍奇金淋巴瘤最常见亚型的生物学和临床管理的当前知识和护理标准。它还强调了在破译疾病发展的分子背景和实施新的治疗方法，特别是那些针对免疫系统的新发现。

英文原文如下：

Abstracts

B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkin lymphomas was last reviewed in The Lancet in 2017, a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients. This Seminar provides an overview of the pathobiology, classification, and prognostication of B-cell non-Hodgkin lymphomas and summarises the current knowledge and standard of care regarding biology and clinical management of the most common subtypes of mature B-cell non-Hodgkin lymphomas. It also highlights new findings in deciphering the molecular background of disease development and the implementation of new therapeutic approaches, particularly those targeting the immune system.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。